Human sarcoma growth is sensitive to small-molecule mediated AXIN stabilization

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  De Robertis, Alessandra ^a,b   Mennillo, Federica ^a,b   Rossi, Marco ^a,b   Valensin, Silvia ^a,b   Tunici, Patrizia ^a,b   Mori, Elisa ^a,b   Caradonna, Nicola ^a   Varrone, Maurizio ^b   Salerno, Massimiliano ^a,b  

^a SienaBiotech   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXIN; AXIN1; BETA CATENIN; MYC PROTEIN; SEN 461; UNCLASSIFIED DRUG; PRIMER DNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXIN2 GENE; CANCER INHIBITION; CD-1 NUDE MOUSE; CDC25A GENE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TUMOR LEVEL; FEMALE; FIBROSARCOMA; FIBROSARCOMA CELL LINE; GENE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL LINE; PROTEIN STABILITY; SARCOMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; CONFOCAL MICROSCOPY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; HUMAN; IMMUNOBLOTTING; LENTIVIRINAE; METABOLISM; NUDE MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AXIN PROTEIN; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; LENTIVIRUS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; PLASMIDS; PROTEIN STABILITY; REAL-TIME POLYMERASE CHAIN REACTION; SARCOMA; WNT SIGNALING PATHWAY;

EID: 84901330436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097847     Document Type: Article

References (51)

1. Nusse R, Varmus HE (1992) Wnt genes. Cell 69: 1073-1087.
2. Nusse R (2005) Wnt signaling in disease and in development. Cell Research 15: 28-32.
3. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell. 17: 9-26.
4. Day TF, Guo X, Garrett-Beal L, Yang Y (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8: 739-50. (Pubitemid 40585296)
5. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 8: 727-38. (Pubitemid 40585295)
6. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, et al. (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17: 1371-84. (Pubitemid 28105516)
7. Stamos JL, Weis WI (2013) The b-catenin destruction complex. Cold Spring Harb. Perspect. Biol. 5 (2013) a007898.
8. Kim SE, Huang H, Zhao M, Zhang X, Zhang A, et al. (2013) Wnt stabilization of b-catenin reveals principles for morphogen receptor-scaffold assemblies. Science 340: 867-70.
9. Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, et al. (2009) The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 28: 500-12.
10. Rui Y, Xu Z, Lin S, Li Q, Rui H, et al. (2004) Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23: 4583-94. (Pubitemid 39657858)
11. Liu W, Rui H, Wang J, Lin S, He Y, et al. (2006) Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J. 25: 1646-58.
12. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-41. (Pubitemid 39014554)
13. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, et al. (1994) Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J. Clin. Oncol. 12: 2614-20. (Pubitemid 24379647)
14. Ferguson WS, Goorin AM (2001) Current treatment of osteosarcoma. Cancer Invest. 19: 292-315. (Pubitemid 32374371)
15. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft tissue sarcomas in adults. N. Engl. J. Med. 353: 701-11.
16. Wunder JS, Torsten ON, Maki RG, O'Sullivan B, Alman BA (2007) Opportunities for improving the therapeutic ratio for patients with sarcoma. The Lancet Oncology 8: 513-524. (Pubitemid 46823060)
17. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314: 1600-6. (Pubitemid 16118216)
18. Iwao K, Miyoshi Y, Nawa G, Yoshikawa H, Ochi T, et al. (1999) Frequent bcatenin abnormalities in bone and soft tissue tumors. Jpn. J. Cancer Res. 90: 205-9. (Pubitemid 29112321)
19. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, et al. (2002) APC mutations in synovial sarcomas. J. Pathol. 196: 445-9.
20. Vijayakumar S, Liu G, Rus IA, Yao S, Chen Y, et al. (2011) High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/b-catenin target gene, CDC25A. Cancer Cell 19: 601-612.
21. Watson LA, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, et al. (2013) Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance. Cancer Discovery 3: 674-689.
22. Gehrke I, Gandhirajan RK, Kreuzer KA (2009) targeting the WNT/betacatenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. Eur. J. Cancer 45: 2759-67.
23. Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-18. (Pubitemid 47359144)
24. Marklein D, Graab U, Naumann I, Yan T, Ridzewski R, et al. (2012) PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. PLoS One 7: e52898.
25. Rubin EM, Guo Y, Tu K, Xie J, Zi X, et al. (2010) Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma. Mol. Cancer Ther. 9: 731-741.
26. Guo Y, Xie J, Rubin E, Tang YX, Lin F, et al. (2008) Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling. Cancer Res. 68: 3350-3360.
27. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J (2008) Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. Journal of Cell Science 121: 737-746. (Pubitemid 351578109)
28. Kawano Y and Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. Journal of Cell Science 116: 2627-2634. (Pubitemid 36857216)
29. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, et al. (2002) Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer 102: 338-42. (Pubitemid 35265873)
30. Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D (2010) High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res. 70: 5399-5408.
31. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-20.
32. Chen B, Dodge ME, Tang W, Lu J, Ma Z, et al. (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5: 100-7.
33. Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, et al. (2013) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Medicine doi:10.1002/cam4.170.
34. De Robertis A, Valensin S, Rossi M, Tunici P, Verani M, et al. (2013) Identification and characterization of a small molecule inhibitor of WNT signaling in glioblastoma cells. Mol. Cancer Ther. 12: 1180-89.
35. James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, et al. (2012) WIKI4, a novel inhibitor of tankyrase and Wnt/b-catenin signaling. PLoS One 7(12): e50457.
36. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL (2010) Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/b-catenin antagonists against human osteosarcoma cells. Invest. New Drugs 28: 766-782.
37. Guadamillas MC, Cerezo A, Del Pozo MA (2011) Overcoming anoikis-pathways to anchorage-independent growth in cancer. J. Cell Sci. 124: 3189-97.
38. Misra RM, Bajaj MS, Kale VP (2012) Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1a-neuropilin-1 axis. PLoS One 7: e50153.
39. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D'Amore PA, et al. (2005) Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A. Cancer Res. 65: 5881-5889. (Pubitemid 40911194)
40. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, et al. (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3: 335-44. (Pubitemid 129643976)
41. Greasley PJ, Bonnard C, Amati B (2000) Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. Nucleic Acids Res. 28: 446-453. (Pubitemid 30057983)
42. Grandori C, Cowley SM, James LP, and Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell. Dev. Biol. 16: 653-699. (Pubitemid 32037520)
43. Van de Wetering M, Sancho E, Verweij C, De Lau W, Oving I, et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2: 241-50. (Pubitemid 35292444)
44. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, et al. (2009) Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-2172.
45. Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI (2009) Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol. Cell. Biol. 29: 5306-5315.
46. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, et al. (2000) AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genetics 24: 245-250. (Pubitemid 30132191)
47. Salahshor S, Woodgett JR (2005) The links between axin and carcinogenesis, J. Clin. Pathol. 58: 225-236. (Pubitemid 40380314)
48. Tarkkanen M, Larramendy ML, Bohling T, Serra M, Hattinger CM, et al. (2006) Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. Eur. J. Cancer 42: 1172-1180.
49. Chen Y, Wu JJ and Huang L (2010) Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy. Mol. Ther. 4: 828-834.
50. Choi SH, Wright JB, Scott AG, and Cole MD (2010) Myc protein is stabilized by suppression of a novel ligase complex in cancer cells. Genes & Dev. 24: 1236-1241.
51. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, et al. (2003) Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 7: 2797-2803. (Pubitemid 36857646)